RASBURICASE

Search structure
Trade Names:
Synonyms:
Status: Approved (2002)
Entry Type: Enzyme
Molecule Category: UNKNOWN
ATC: V03AF07
UNII: 08GY9K1EUO

Pharmacology

Action Mechanism of Action Reference
OXIDATIVE ENZYME Uric acid oxidative enzyme DailyMed

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Gout 4 D006073 ClinicalTrials
Tumor Lysis Syndrome 3 D015275 ClinicalTrials
Hyperuricemia 3 D033461 ClinicalTrials
Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 D054198 ClinicalTrials
Lymphoma, Large B-Cell, Diffuse 2 D016403 ClinicalTrials
Lymphoma, Large-Cell, Anaplastic 2 D017728 ClinicalTrials
Burkitt Lymphoma 2 D002051 ClinicalTrials

Side Effects from Label

Side effects Relative Frequency (%) Labels
Gastrointestinal disorders Nausea 57.6
Gastrointestinal disorders Vomiting 55.6
Gastrointestinal disorders Nausea 54.9
Cardiac disorders Oedema peripheral 50.0
Gastrointestinal disorders Vomiting 50.0
Gastrointestinal disorders Vomiting 46.6
Investigations Body temperature increased 46.0
Cardiac disorders Oedema peripheral 42.9
Investigations Body temperature increased 40.7
Gastrointestinal disorders Vomiting 38.0
Investigations Body temperature increased 37.5
Gastrointestinal disorders Vomiting 36.0
Gastrointestinal disorders Nausea 33.3
Investigations Body temperature increased 32.0
Gastrointestinal disorders Nausea 30.9
Gastrointestinal disorders Vomiting 30.8
Gastrointestinal disorders Diarrhoea 29.6
Gastrointestinal disorders Nausea 27.0
Nervous system disorders Headache 26.0
Nervous system disorders Headache 25.9
Gastrointestinal disorders Abdominal pain 25.3
Gastrointestinal disorders Gastrointestinal pain 25.3
Nervous system disorders Headache 25.3
Gastrointestinal disorders Nausea 24.0
Psychiatric disorders Anxiety 23.9
Skin and subcutaneous tissue disorders Dermatitis 23.4
Skin and subcutaneous tissue disorders Rash 23.4
Gastrointestinal disorders Abdominal pain 21.7
Gastrointestinal disorders Gastrointestinal pain 21.7
Gastrointestinal disorders Abdominal pain 20.0
Gastrointestinal disorders Constipation 20.0
Gastrointestinal disorders Diarrhoea 20.0
Gastrointestinal disorders Gastrointestinal pain 20.0
Gastrointestinal disorders Diarrhoea 19.4
Investigations Alanine aminotransferase increased 17.6
Psychiatric disorders Anxiety 17.6
Metabolism and nutrition disorders Hypophosphataemia 17.4
Metabolism and nutrition disorders Hypophosphataemia 16.5
Blood and lymphatic system disorders Hyperbilirubinaemia 16.3
Gastrointestinal disorders Diarrhoea 16.0
General disorders and administration site conditions Mucosal inflammation 15.0
Skin and subcutaneous tissue disorders Dermatitis 14.8
Skin and subcutaneous tissue disorders Rash 14.8
Respiratory, thoracic and mediastinal disorders Laryngeal pain 14.1
Skin and subcutaneous tissue disorders Dermatitis 13.0
Skin and subcutaneous tissue disorders Rash 13.0
Skin and subcutaneous tissue disorders Dermatitis 12.0
Cardiac disorders Fluid overload 12.0
Nervous system disorders Headache 12.0
Immune system disorders Hypersensitivity 12.0
Skin and subcutaneous tissue disorders Rash 12.0
Infections and infestations Sepsis 12.0
Investigations Alanine aminotransferase increased 10.9
Respiratory, thoracic and mediastinal disorders Laryngeal pain 9.9
Metabolism and nutrition disorders Hyperphosphataemia 9.8
Metabolism and nutrition disorders Hyperphosphataemia 8.8
Gastrointestinal disorders Nausea 8.0
Blood and lymphatic system disorders Hyperbilirubinaemia 7.7
Investigations Body temperature increased 6.6
Metabolism and nutrition disorders Hypophosphataemia 6.6
Cardiac disorders Oedema peripheral 6.6
Metabolism and nutrition disorders Hypophosphataemia 6.5
Infections and infestations Sepsis 6.5
Infections and infestations Sepsis 5.4
Blood and lymphatic system disorders Hyperbilirubinaemia 4.4
Infections and infestations Sepsis 4.4
Gastrointestinal disorders Abdominal pain 4.3
Investigations Alanine aminotransferase increased 4.3
Gastrointestinal disorders Gastrointestinal pain 4.3
Metabolism and nutrition disorders Hypophosphataemia 4.3
Investigations Body temperature increased 4.0
Gastrointestinal disorders Diarrhoea 4.0
Gastrointestinal disorders Vomiting 4.0
Skin and subcutaneous tissue disorders Dermatitis 3.7
Immune system disorders Hypersensitivity 3.7
Gastrointestinal disorders Nausea 3.7
Skin and subcutaneous tissue disorders Rash 3.7
Gastrointestinal disorders Vomiting 3.7
Gastrointestinal disorders Abdominal pain 3.3
Investigations Alanine aminotransferase increased 3.3
Psychiatric disorders Anxiety 3.3
Cardiac disorders Fluid overload 3.3
Gastrointestinal disorders Gastrointestinal pain 3.3
Blood and lymphatic system disorders Hyperbilirubinaemia 3.3
Cardiac disorders Oedema peripheral 3.3
Immune system disorders Hypersensitivity 2.5
Gastrointestinal disorders Abdominal pain 2.2
Investigations Alanine aminotransferase increased 2.2
Gastrointestinal disorders Gastrointestinal pain 2.2
Blood and lymphatic system disorders Hyperbilirubinaemia 2.2
Gastrointestinal disorders Nausea 2.2
Cardiac disorders Oedema peripheral 2.2
Gastrointestinal disorders Nausea 1.6
Skin and subcutaneous tissue disorders Dermatitis 1.4
Skin and subcutaneous tissue disorders Rash 1.4
Gastrointestinal disorders Vomiting 1.3
Cardiac disorders Fluid overload 1.1
Metabolism and nutrition disorders Hyperphosphataemia 1.1
Respiratory, thoracic and mediastinal disorders Laryngeal pain 1.1
Gastrointestinal disorders Nausea 1.1
Gastrointestinal disorders Vomiting 1.1
Immune system disorders Anaphylactic shock 1.0
Immune system disorders Bronchospasm 1.0
Immune system disorders Hypersensitivity 1.0
Vascular disorders Hypotension 1.0
Skin and subcutaneous tissue disorders Dermatitis 0.9
Gastrointestinal disorders Diarrhoea 0.9
Nervous system disorders Headache 0.9
Skin and subcutaneous tissue disorders Rash 0.9
Immune system disorders Hypersensitivity 0.6
Immune system disorders Anaphylactic shock 0.1
Infections and infestations Rhinitis 0.1

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
General disorders and administration site conditions
19.57
Injury, poisoning and procedural complications
14.89
Respiratory, thoracic and mediastinal disorders
10.64
Cardiac disorders
10.21
Blood and lymphatic system disorders
7.23
Metabolism and nutrition disorders
6.81
Congenital, familial and genetic disorders
4.68
Musculoskeletal and connective tissue disorders
4.68
Investigations
3.4
Renal and urinary disorders
3.4
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
2.55
Gastrointestinal disorders
2.13
Hepatobiliary disorders
2.13
Immune system disorders
2.13
Vascular disorders
2.13

Cross References

Resources Reference
CAS NUMBER 134774-45-1
ChEMBL CHEMBL1201594
FDA SRS 08GY9K1EUO
Guide to Pharmacology 7467
CONTENTS